Beyond Venture Capital - Industry Report – 2nd Edition

Beyond Venture Capital: How European Science Ventures Have Grown Without the Startup Script

Industry Report, 2nd Edition — Maria Ksenia Witte, Arise Innovations®

Venture capital is often treated as the default route for turning science into industry. But what if the real question is not whether a venture can raise VC, but whether VC fits the venture’s actual state, risks, commercialisation clock and path to scale?

Beyond Venture Capital examines 100 European science- and technology-based companies whose formative commercial capabilities were built without institutional venture capital as the dominant financing architecture.

The report does not argue that VC is inherently good or bad. It shows that capital is effective only when its return logic, time horizon, governance requirements and risk appetite match the venture it is expected to finance. For many science ventures, physical validation, certification, manufacturing learning, procurement and systems integration develop on timelines that conventional fund structures cannot easily accommodate.

Drawing on a structured comparative case base, the report identifies ten recurring capital architectures beyond the standard VC model, including:

• Founder and family compounding
• Revenue before scale
• Customer advances and procurement
• Supplier credit, leasing and asset finance
• Grants and mission-oriented capital
• Licensing and IP-first models
• Corporate spinouts and strategic platforms
• Management buyouts and carve-outs
• Foundation and long-term ownership
• Public markets after validation

Ten detailed case studies, including Arm, Sensirion, Brainlab, Menlo Systems, WITec, Endress+Hauser, StreetScooter and Raspberry Pi, demonstrate how different actors financed different risks at different stages.

The report also includes a 100-company evidence register, exclusions and counter-cases, a transparent qualification protocol, and practical implications for founders, investors, universities, technology-transfer offices, public funders, corporates and boards.

The central conclusion is simple but consequential:

Capital should finance the next scarce capability, not generic activity.

This report is for decision-makers who need to understand how science ventures actually mature, which forms of capital fit which risks, and why a strong company may still be a poor fit for a particular fund model.

Second edition | Research cut-off: 17 August 2026

Copyright © 2026 Maria Ksenia Witte and Arise Innovations®. Purchase provides access to the report for individual professional reference. No licence to reproduce, redistribute, commercialise or reconstruct protected methods or proprietary implementation logic is granted.